Controlled Trial of Suloctidil in Intermittent Claudication

Verhaeghe, Raymond; Hoof, A Van; Beyens, Georges

doi:10.1097/00005344-198103000-00006

Cited by 24 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In eight studies 27,32,44,48,50,51,56,59 patients lost to follow-up accounted for 5 per cent or less of the respective study populations. In four trials 24,39,46,64 patients lost to follow-up accounted for more than 10 per cent of the respective study populations.…”

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease

Robless

Mikhailidis

Stansby

2001

British Journal of Surgery

164

114

View full text Add to dashboard Cite

show abstract

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

“…Five trials of one antiplatelet treatment (aspirin) against another antiplatelet regimen (aspirin Mortality data were available either from the published study or through contact with the authors. In 12 studies there were no deaths in either the antiplatelet or placebo groups 23,31,33,34,46,48,51,53,60,61,63,64 .…”

Section: Description Of Studiesmentioning

confidence: 98%

Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease

Robless

Mikhailidis

Stansby

2001

British Journal of Surgery

164

114

View full text Add to dashboard Cite

show abstract

“…Total walking distance was assessed with aspirin (22), ticlopidine (17,30), suloctidil (34)(35)(36), indobufen (41), and defibrotide (58-60), and results were similar to those observed for pain-free walking distance, but did not reach statistical significance, except for indobufen and defibrotide, which increased total walking distance for a (common) difference of the means equal to 98.3 m (95% C.I., 49.2-147), and to 88.8 m (95% C.I., 45-132.6), respectively (41,(58)(59)(60). In one study (43), triflusal increased total walking distance of 53.2 m compared to placebo (p = 0.05).…”

Section: Active Treatment Versus Controlmentioning

confidence: 99%

Antithrombotic Drugs in the Primary Medical Management of Intermittent Claudication: A Meta-analysis

Girolami¹,

Bernardi²,

Prins³

et al. 1999

Thromb Haemost

View full text Add to dashboard Cite

Summary Background. There is no consensus on the efficacy of the antithrombotic drugs available for patients with intermittent claudication. Methods. A Medline and manual search was used to identify relevant publications. Uncontrolled or retrospective studies, double reports or trials without clinical outcomes were excluded. Included studies were graded as level 1 (randomised and double- or assessor-blind), level 2 (open randomised), or level 3 (non-randomised comparative). Mortality, cerebro- or cardiovascular events, amputations, arterial occlusions or number of revascularization procedures performed in the lower limbs, pain-free and total walking distance, ankle brachial index and calf blood flow, were the main outcomes considered. When feasible, end of treatment results, either continuous or binary, were combined with appropriate statistical methods. Results. Mortality was significantly decreased by ticlopidine compared to placebo (common odds ratio 0.68, 95% C.I., 0.49 - 0.95); clopidogrel decreased vascular events in comparison to aspirin (odds ratio 0.76, 95% C.I., 0.63 - 0.92) in level 1 studies. Arterial occlusions and the number of revascularization procedures performed were statistically significantly decreased by aspirin and ticlopidine, respectively. A small but statistically significant improvement in pain-free walking distance was determined by picotamide, indobufen, low molecular weight heparins, sulodexide and defibrotide, in small studies. Conclusions. Clopidogrel and ticlopidine do reduce clinically important events in patients with intermittent claudication and could be added to the primary medical treatment of these patients. The use of aspirin in these patients cannot be based on direct evidence, but only on analogy with coronary and cerebral atherosclerosis, where it has documented efficacy. Other antithrombotic drugs were not properly evaluated in patients with intermittent claudication.

show abstract

“…Other agents subjected to randomized clinical trials that were found to be ineffective in the treatment of intermittent claudication include the antiserotonin agent ketanserin, 58 suloctidil, 59 nifedipine, 60 fish oil supplementation, 61 naftidrofuryl, 62,63 and ethylenediaminetetraacetic acid chelation therapy. 64,65 A promising drug is l-carnitine, an agent that appears to facilitate the transfer of acylated fatty acids and acetate across mitochondrial membranes, thereby enhancing available energy stores and improving oxidative muscle metabolism.…”

Section: Other Agentsmentioning

confidence: 99%